Introducing LucenceINSIGHT™

LucenceINSIGHT™ is a multi-cancer earlydetection (MCED) tool that screens for thecirculating tumor DNA (ctDNA) of up to 50cancers in one simple blood draw.

It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.
‍
The result is cross examined with machine-learning to study the cancer signal profile. Utilizing data from the analysis, the test reports a presence or absence of a cancer signal. A localization signal is also derived and used to predict up to 2 sites where the cancer signal might have originated from (“Predicted Signal Localization”). The report will present the result as Predicted Signal Localization, with an accuracy of 88%.
‍

AmpliMarkTM Upgrade (Lucence Mirror Barcodes)

How does it work?

LucenceINSIGHT™ is based on a proprietary amplicon-based technology to screen for the signal of cancer with a specificity of 99.2%.

The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%.

LucenceINSIGHTTM screens for cancer withlow false positives compared to tumormarker proteins.

A report is generated in 12 or 18 working days.

Why screen for cancer early?

1. Early Detection Leads to Better Outcomes

2. Cancer is the number 1 killer.¹

3. 4 in 5 cancer deaths are not covered by recommended screening.^3,4

4. 5-year survival is higher with early detection.⁵

Who is it recommended for?

LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:

Real-world Evidence of LucenceINSIGHT™